Finanzen von Legend Biotech Corp (LEGN)LEGNLegend Biotech Corp

Evaluating the bottom line, Legend Biotech Corporation maintains a gross margin of 64.54%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.89%, while the net margin is 8.57%. These profitability ratios, combined with a Return on Equity (ROE) of -8.09%, provide a clear picture of how effectively LEGN converts its operational activities into shareholder value.

In the context of the broader market, LEGN competes directly with industry leaders such as VKTX and OGN. With a market capitalization of $3.59B, it holds a significant position in the sector. When comparing efficiency, LEGN's gross margin of 64.54% stands against VKTX's N/A and OGN's 54.36%. Such benchmarking helps identify whether Legend Biotech Corporation is trading at a premium or discount relative to its financial performance.

Legend Biotech's revenue surged to $387.5 million in Q2 2026, a 52% increase year-over-year, and the gross margin improved to 64.54%. However, the company has faced net income losses in previous quarters, with a recent profit of $33.2 million indicating a turnaround.